Early Angiotensin II in the Emergency Department (ANGIO-ED)
ANGIOtensin II for Septic Shock in the Emergency Department: ANGIO-ED Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Brett Faine, PharmD
- Phone Number: +1 319 356 2577
- Email: brett-faine@uiowa.edu
Study Locations
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Recruiting
- University of Iowa Hospitals and Clinics
-
Contact:
- Brett Faine
- Phone Number: 3193108067
- Email: brett-faine@uiowa.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Age ≥18; and
- Requiring norepinephrine at a dose of 0.05-0.25 mcg/kg/min mcg/kg/minute despite adequate fluid resuscitation; and
- Receiving intravenous antibiotics or clinician's intention to administer antibiotics at the time of enrollment; and
- Can provide written informed consent (or legally authorized representative).
Exclusion Criteria
- Acute coronary syndrome;
- Cardiogenic shock;
- Patients with a history of mesenteric ischemia;
- Patients with a history of having an aortic dissection or abdominal aortic aneurysm;
- Patients with an expected lifespan of <12 hours;
- Patients with hemorrhagic shock (e.g., actively receiving transfusion of packed red blood cells);
- Active administration of two vasoactive agents before enrollment; and
- Pre-existing thromboembolic disease or inability to tolerate pharmacologic VTE prophylaxis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Angiotensin II Infusion
|
Angiotensin II continuous infusion
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility of completing all clinical trial activities
Time Frame: From enrollment to the end of treatment up to 6 hours after the angiotensin II infusion is initiated
|
Percentage of patients who provide informed consent and receive angiotensin II infusion in the emergency department
|
From enrollment to the end of treatment up to 6 hours after the angiotensin II infusion is initiated
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean arterial pressure response
Time Frame: 60 minutes after the intiation of angiotensin II infusion
|
Change in mean arterial pressure
|
60 minutes after the intiation of angiotensin II infusion
|
|
Mean norepinephrine dose (during angiotensin II infusion)
Time Frame: 60 minutes after the intiation of angiotensin II infusion
|
Change in norepinephrine dose (mcg/kg/minute) after the initiation of angiotensin II infusion
|
60 minutes after the intiation of angiotensin II infusion
|
|
Mean norepinephrine dose (post angiotensin II infusion)
Time Frame: 60 minutes after the completion of the angiotensin II infusion
|
Mean norepinephrine dose (mcg/kg/minute) after the completion of the angiotensin II infusion
|
60 minutes after the completion of the angiotensin II infusion
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, Busse LW, Altaweel L, Albertson TE, Mackey C, McCurdy MT, Boldt DW, Chock S, Young PJ, Krell K, Wunderink RG, Ostermann M, Murugan R, Gong MN, Panwar R, Hastbacka J, Favory R, Venkatesh B, Thompson BT, Bellomo R, Jensen J, Kroll S, Chawla LS, Tidmarsh GF, Deane AM; ATHOS-3 Investigators. Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med. 2017 Aug 3;377(5):419-430. doi: 10.1056/NEJMoa1704154. Epub 2017 May 21.
- Chawla LS, Busse L, Brasha-Mitchell E, Davison D, Honiq J, Alotaibi Z, Seneff MG. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Crit Care. 2014 Oct 6;18(5):534. doi: 10.1186/s13054-014-0534-9.
- Wieruszewski PM, Bellomo R, Busse LW, Ham KR, Zarbock A, Khanna AK, Deane AM, Ostermann M, Wunderink RG, Boldt DW, Kroll S, Greenfeld CR, Hodges T, Chow JH; Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3) Investigators. Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial. Crit Care. 2023 May 5;27(1):175. doi: 10.1186/s13054-023-04446-1.
- Avni T, Lador A, Lev S, Leibovici L, Paul M, Grossman A. Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis. PLoS One. 2015 Aug 3;10(8):e0129305. doi: 10.1371/journal.pone.0129305. eCollection 2015.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Sepsis
- Systemic Inflammatory Response Syndrome
- Inflammation
- Shock
- Pathological Conditions, Signs and Symptoms
- Shock, Septic
- Molecular Mechanisms of Pharmacological Action
- Protease Inhibitors
- Enzyme Inhibitors
- Serine Proteinase Inhibitors
- Vasoconstrictor Agents
- Giapreza
- Angiotensin II
- Angiotensinogen
Other Study ID Numbers
Other Study ID Numbers
- 202406277
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.